Stock A082800 VIVOZON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Vivozon Pharmaceutical Co., Ltd.

Equities

A082800

KR7082800004

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
3,060 KRW -0.81% Intraday chart for Vivozon Pharmaceutical Co., Ltd. +3.90% +2.00%
2023 Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023. CI
2023 Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023.
CI
Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares.
CI
Vivozon Pharmaceutical Co., Ltd. announces an Equity Buyback for 5,000,000 shares.
CI
Vivozon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Vivozon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 2.000000072 billion in funding
CI
Vivozon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 2.000000072 billion in funding
CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 6 billion in funding
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 6 billion in funding
CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) dropped from S&P Global BMI Index
CI
Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors
CI
Vivozon Healthcare, Inc. announced that it has received KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.
CI
Osung Advanced Materials Co., Ltd. cancelled the acquisition of Rumi Technology & Loan CO.,LTD. from Lumimicro Co., Ltd for KRW 33.7 billion.
CI
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd from Osung Advanced Materials Co., Ltd. and S-MAC CO., Ltd..
CI
Vivozon Healthcare, Inc. announced that it has received KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.
CI
Lumimicro Co., Ltd completed the acquisition of 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others.
CI
Lumimicro Co., Ltd agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others for KRW 60.9 billion.
CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A082800 Stock
  4. News Vivozon Pharmaceutical Co., Ltd.